On 20 December 2017, the French Competition Authority (the FCA) imposed a EUR 25 million fine on a pharmaceutical laboratory, for delaying entry onto the market of the generic version of Durogesic, and for hindering its development through a disparagement campaign.
No public version of the decision is available yet, nonetheless the FCA has already published a detailed press release (available in French).
Durogesic is a powerful opioid analgesic, which active substance is fentanyl, usually prescribed in the form of transdermal patch for the treatment of severe pain, including chronic cancer pain. In 2007, a competing pharmaceutical company launched its generic equivalent.
Continue Reading French Competition Authority Fines a Pharmaceutical Laboratory EUR 25 Million for Anti-Generic Practices